Fig. 4
From: The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Approaches for building PARP-inhibitor-resistant cancer cell lines. In preclinical trials, the construction of PARP inhibitor-resistant cancer cell lines was performed primarily by exploiting the following three mechanisms: a preexisting intrinsic PARP inhibitor resistance; b acquired PARP inhibitor resistance under extended and constant PARP inhibitor exposure; c de novo PARP inhibitor resistance via knockout or knockdown of key genes related to PARP inhibitor resistance. PARPi-resistance PARP inhibitor resistance; MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CCK-8 Cell counting Kit-8; CFA Colony formation assay